Evidence map›Paper›PMID 19616076›Full record

ReviewBiochimica et biophysica acta2010

Dynamics of galectin-3 in the nucleus and cytoplasm.

Kevin C Haudek, Kimberly J Spronk, Patricia G Voss, Ronald J Patterson, John L Wang, Eric J Arnoys

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 2 syntheses or guidelines pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026
    Review
  4. Article
  5. Chimerolectins: Classification, structural architecture, and functional perspectives.Protein science : a publication of the Protein Society · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Galectin-3: action and clinical utility in chronic kidney disease.International urology and nephrology · 2024
    Review
  12. Article
  13. Lysosome quality control in health and neurodegenerative diseases.Cellular & molecular biology letters · 2024
    Review
  14. Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer.International journal of molecular sciences · 2024
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kevin C HaudekDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.
Kimberly J Spronk
Patricia G Voss
Ronald J Patterson
John L Wang
Eric J Arnoys
Michigan State University · USCalvin University · US

Funding

CARBOHYDRATE-BINDING PROTEIN 35R01GM038740 · NIGMS · MICHIGAN STATE UNIVERSITY · PI WANG, JOHN L · 1988 to 2006
$1.3M
NIGMS NIH HHS GM-38740NIGMS NIH HHS R01 GM038740
6 · The paper itself

Abstract

This review summarizes selected studies on galectin-3 (Gal3) as an example of the dynamic behavior of a carbohydrate-binding protein in the cytoplasm and nucleus of cells. Within the 15-member galectin family of proteins, Gal3 (M(r) approximately 30,000) is the sole representative of the chimera subclass in which a proline- and glycine-rich NH(2)-terminal domain is fused onto a COOH-terminal carbohydrate recognition domain responsible for binding galactose-containing glycoconjugates. The protein shuttles between the cytoplasm and nucleus on the basis of targeting signals that are recognized by importin(s) for nuclear localization and exportin-1 (CRM1) for nuclear export. Depending on the cell type, specific experimental conditions in vitro, or tissue location, Gal3 has been reported to be exclusively cytoplasmic, predominantly nuclear, or distributed between the two compartments. The nuclear versus cytoplasmic distribution of the protein must reflect, then, some balance between nuclear import and export, as well as mechanisms of cytoplasmic anchorage or binding to a nuclear component. Indeed, a number of ligands have been reported for Gal3 in the cytoplasm and in the nucleus. Most of the ligands appear to bind Gal3, however, through protein-protein interactions rather than through protein-carbohydrate recognition. In the cytoplasm, for example, Gal3 interacts with the apoptosis repressor Bcl-2 and this interaction may be involved in Gal3's anti-apoptotic activity. In the nucleus, Gal3 is a required pre-mRNA splicing factor; the protein is incorporated into spliceosomes via its association with the U1 small nuclear ribonucleoprotein (snRNP) complex. Although the majority of these interactions occur via the carbohydrate recognition domain of Gal3 and saccharide ligands such as lactose can perturb some of these interactions, the significance of the protein's carbohydrate-binding activity, per se, remains a challenge for future investigations.

Indexed as

Amino Acid SequenceAnimalsApoptosis Regulatory ProteinsCell Line, TumorCell NucleusCytoplasmExportin 1 ProteinGalectin 3HumansKaryopherinsLigandsNuclear Export SignalsReceptors, Cell SurfaceReceptors, Cytoplasmic and NuclearRibonucleoproteinsSpliceosomesApoptosis Regulatory ProteinsExportin 1 ProteinGalectin 3KaryopherinsLigandsNuclear Export SignalsReceptors, Cell SurfaceReceptors, Cytoplasmic and NuclearRibonucleoproteinssaccharide-binding proteins

Identifiers

PMID19616076
PMCPMC2815258
OpenAlexW1975776751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.